

Michigan Pharmacy and Therapeutics Committee  
Meeting of Tuesday, September 1, 2009, 6 PM  
Kellogg Center, Michigan State University  
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Introductions:

Committee members present: Drs. Nedd, Thill, Bradley, Dillon, Arend, Fiechtner, Perri

First Health staff present: Annette Paul, RPh, Donna Johnson, RPh

State staff present: Debera Eggleston, MD, Max Robins, DO, Helen Walley, Carla Patrick-Fagan

DUR Board: Karen Jonas, RPh

The minutes of the June 2, 2009 and July 21, 2009 meetings were approved

New Drug Reviews and Line Extensions:

Following review and discussion, including input from M. Finton, MD, representing UCB pharmaceuticals, K. Barrett, MD, on behalf of Kapidex, and V. Rozenfeld, PharmD, Watson labs on behalf of Gelnique the Committee recommends to the Department the following:

**Aplenzin:** add to the Michigan Pharmaceutical Product List (MPPL); the Committee wanted to add a prior authorization requirement for this form of bupropion, but the Department is precluded from doing so by legislation on antidepressant medications

**Rapaflo:** add to the MPPL and to the Preferred Drug List (PDL) with prior authorization (PA)

**Acanya:** this drug remains non formulary because the manufacturer has not signed a rebate agreement with the federal government

**Vimpat:** add to the MPPL with an electronic edit that looks for use of first line anti-epileptic drugs

**Toviaz;** add to the PDL with PA

**Apriso;** add to the PDL with PA

**Uloric:** add to the MPPL with an electronic edit looking for use of allopurinol, probenecid products

**Promacta:** add to the MPPL

**Kapidex:** add to the PDL with PA; the Department will research if a different timeframe from other proton pump inhibitors is necessary as part of the PA process for maintenance use of this drug

**Vectical;** add to the MPPL with a maximum quantity limit as stated in its licensure

**Degaralix:** this would be a physician service

**Afinitor:** add to the MPPL

**Lamictal XR and ODT:** add to the MPPL

**Lo-Seasonique:** add to the MPPL

**Ryzolt ER:** add to the PDL with PA

**Gelnique 10% gel:** add to the PDL with PA; the Miscellaneous Workgroup will be asked to review the Urinary Antispasmodics class for December to clarify those products' status

Review of Preferred Drug List Classes:

The Committee reviewed the workgroup recommendations and recommended the Department adopt the Workgroup recommendations for the drug classes included in:

Diabetes Drugs  
Gastrointestinal Drugs  
Miscellaneous Drugs

Public Comment The following persons made comment:

E. Eby, MPH, Lilly, Cymbalta  
V. Rozenfeld, PharmD, Watson, Rapaflo  
H. Fehmi, MD, Genzyme, Renvela  
C. Beals, MD, Savella  
D. Minecan, MD, Vimpat  
A. Gorelick, MPH, Epilepsy Foundation, Vimpat, Lamictal XR, ODT  
D. Iacobellis, PharmD, Pfizer, Celebrex, Lyrica

The Committee requested that a workgroup review and bring back recommendations for a Fibromyalgia class on the Preferred Drug List as part of the December meeting discussions. The Department will incorporate this as part of the CNS and Analgesics workgroup assignments.

Next Meeting: Tuesday, December 1, 2009